Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction.Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by Galaxy-Sirius…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
